Computational chemistry

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

Retrieved on: 
Monday, August 28, 2023
Probability, G protein-coupled receptor, Computational chemistry, Medicine, TPP, Faster-than-light, Cony, Doctor of Philosophy, Chemistry, GPCR, MD, Machine learning, Drug discovery, SVP, Insight Partners, Pharmaceutical industry, Management, Operation, Biology, NVIDIA

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Superluminal Medicines Inc., a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created, today announced the closing of a $33 million funding round. The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA. Gaingels also joined in the financing.

Key Points: 
  • The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA.
  • The funding will be used to progress Superluminal’s pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor (GPCR) targets.
  • "We are grateful to have the support of prominent investors as we set new expectations for the speed, accuracy and cost-effectiveness of drug discovery and development," said Cony D'Cruz, CEO of Superluminal Medicines.
  • “Superluminal's ingenuity in combining biology, chemistry and technology holds immense potential to accelerate drug discovery and increase the probability of success in small molecule drug development.

Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ruxolitinib, Novartis Institute for Tropical Diseases, Mayo Clinic, University, Oncology Drug Advisory Committee, Journal of Clinical Oncology, JAK, Type 2, Bone marrow, FACP, ODAC, Multimedia, Biomedical Research, Computational chemistry, Dana–Farber Cancer Institute, MDS, Harvard Medical School, Pancreatic serous cystadenoma, Bone marrow failure, Journal, Ajax, MD, Translational research, American Society of Hematology, Patient, Division, Edward, Memorial Sloan Kettering Cancer Center, Clinical professor, Research, FDA, Therapy, Malignancy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Myelodysplastic syndrome, Disease, Pharmaceutical industry, Nursing, Hematology, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230823046723/en/
    Ajax Therapeutics CMO David Steensma, MD, FACP (Photo: Business Wire)
    “We are very fortunate to have such a veteran hematology drug developer as David join the Ajax team as we near the clinic with our next generation Type II JAK2 inhibitor program for MPNs,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Dr. Steensma has published over 200 original research papers as well as numerous reviews, editorials and book chapters.
  • He received his medical degree from the University of Chicago’s Pritzker School of Medicine.

High-Throughput Computing on Rescale Enables Innovation at Scale with Multi-Cloud Accelerated Computing

Retrieved on: 
Tuesday, August 22, 2023
Cloud, Data management, Grace Hopper, Feminism and modern architecture, Arm, Deep learning, Cloud computing, Intelligence, Microsoft, Research, IP, Architecture, Computational chemistry, HTC, Organization, Running, Data analysis, NVIDIA, Machine learning, Google Cloud, Engineering, SAN, Workload, Drug discovery, Azure, AI, Ecosystem, AWS, Annapurna Labs, Industrial and production engineering, Automation, High-throughput computing, Computer data storage, Video game, Rescale

SAN FRANCISCO, Aug. 22, 2023 /PRNewswire/ -- Rescale, the leader in high-performance computing built for the cloud, announces High-Throughput Computing (HTC), a new capability on Rescale's platform for running massively parallel computational jobs such as those used in semiconductor verification analysis, bioinformatics pipelines, and design space exploration.

Key Points: 
  • "Rescale is helping Arm usher in a new era for chip design," says Mark Galbraith, Arm's VP of Productivity Engineering.
  • Cloud computing creates new possibilities for R&D organizations to use HTC at unprecedented scale.
  • To fully capture these benefits, organizations need sophisticated and robust management capabilities to securely manage HTC tasks across multiple cloud services and computing architectures.
  • says Joris Poort, CEO of Rescale, "Arm is a great example of how Rescale is working with leading companies to accelerate innovation with the power of intelligent computing across clouds.

AMD Showcases Leadership Cloud Performance with New Amazon EC2 Instances Powered by 4th Gen AMD EPYC Processors

Retrieved on: 
Friday, August 18, 2023
Cloud, Central Information Technology Office, Amazon Web Services, Amazon Elastic Compute Cloud, AMD, Female gendering of AI technologies, Intelligence, M7, Computational chemistry, DDR5, Forecasting, DDR4, Amazon, AMD EPYC, Half-precision floating-point format, VNNI, EC2, HPC, DTN, DNT, Weather, AWS, Memory, TrueCar, Video game

SANTA CLARA, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced Amazon Web Services (AWS) has expanded its 4th Gen AMD EPYC™ processor-based offerings with the general availability of Amazon Elastic Compute Cloud (EC2) M7a and Amazon EC2 Hpc7a instances, which offer next-generation performance and efficiency for applications that benefit from high performance, high throughput and tightly coupled HPC workloads, respectively.

Key Points: 
  • —Amazon EC2 Hpc7a instances, powered by 4th Gen AMD EPYC processors, deliver up to 2.5x better performance compared to Amazon EC2 Hpc6a instances—
    SANTA CLARA, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced Amazon Web Services (AWS) has expanded its 4th Gen AMD EPYC™ processor-based offerings with the general availability of Amazon Elastic Compute Cloud (EC2) M7a and Amazon EC2 Hpc7a instances , which offer next-generation performance and efficiency for applications that benefit from high performance, high throughput and tightly coupled HPC workloads, respectively.
  • “For customers with increasingly complex and compute-intensive workloads, 4th Gen EPYC processor-powered Amazon EC2 instances deliver a differentiated offering for customers,” said David Brown, vice president of Amazon EC2 at AWS.
  • Amazon EC2 Hpc7a instances are designed for tightly coupled high performance computing workloads and deliver 2.5x better performance compared to Amazon EC2 Hpc6a instances.
  • With these new instances, AWS customers can continue to take advantage of the excellent performance, scalability, and efficiency offered by AMD EPYC processors.

SYGNATURE DISCOVERY ACCELERATES GLOBAL GROWTH WITH MAJOR NORTH AMERICAN ACQUISITION

Retrieved on: 
Tuesday, August 1, 2023
Partnership, FTQ, Drug discovery, Arrows, Pharming, Business Development Bank of Canada, Computational chemistry, Acquisition, Patent, DMPK, VCS, Biology, Pharmacology, Pharmaceutical industry

NOTTINGHAM, England, Aug. 1, 2023 /PRNewswire/ -- Leading integrated drug discovery partner, Sygnature Discovery ("Sygnature") has announced its acquisition of one of North America's largest discovery Contract Research Organisations, Canada-based NuChem Sciences.

Key Points: 
  • NOTTINGHAM, England, Aug. 1, 2023 /PRNewswire/ -- Leading integrated drug discovery partner, Sygnature Discovery ("Sygnature") has announced its acquisition of one of North America's largest discovery Contract Research Organisations, Canada-based NuChem Sciences.
  • The transaction creates a significant competitive advantage for Sygnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market.
  • Together, Sygnature Discovery and NuChem are creating a global force that delivers drug discovery expertise to support customer programmes from target validation through to candidate selection, combining the best of North American and UK operations.
  • Dr Simon Hirst, CEO at Sygnature Discovery, commented: "This acquisition represents a pivotal milestone in the Sygnature growth plan, allowing us to deliver better discovery solutions to customers around the world.

SYGNATURE DISCOVERY ACCELERATES GLOBAL GROWTH WITH MAJOR NORTH AMERICAN ACQUISITION

Retrieved on: 
Tuesday, August 1, 2023
Partnership, FTQ, Drug discovery, Arrows, Pharming, Business Development Bank of Canada, Computational chemistry, Acquisition, Patent, DMPK, VCS, Biology, Pharmacology, Pharmaceutical industry

NOTTINGHAM, England, Aug. 1, 2023 /PRNewswire/ -- Leading integrated drug discovery partner, Sygnature Discovery ("Sygnature") has announced its acquisition of one of North America's largest discovery Contract Research Organisations, Canada-based NuChem Sciences.

Key Points: 
  • NOTTINGHAM, England, Aug. 1, 2023 /PRNewswire/ -- Leading integrated drug discovery partner, Sygnature Discovery ("Sygnature") has announced its acquisition of one of North America's largest discovery Contract Research Organisations, Canada-based NuChem Sciences.
  • The transaction creates a significant competitive advantage for Sygnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market.
  • Together, Sygnature Discovery and NuChem are creating a global force that delivers drug discovery expertise to support customer programmes from target validation through to candidate selection, combining the best of North American and UK operations.
  • Dr Simon Hirst, CEO at Sygnature Discovery, commented: "This acquisition represents a pivotal milestone in the Sygnature growth plan, allowing us to deliver better discovery solutions to customers around the world.

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Retrieved on: 
Monday, July 31, 2023
ABA, University, Autumn, Ontario Centre of Forensic Sciences, Partnership, CSE, Spectrum, Autism spectrum, Medicine, University of Arkansas for Medical Sciences, MDXX, Hope, Innovation, Research, Composition of matter, IP, Computational chemistry, CNS, Drug design, Central nervous system, MDMA, Patent, ASD, NCE, ALA, Psychedelic drug, OTC, Drug discovery, Psychiatry, Social anxiety, Safety, Pharmaceutical industry, Pharmacology

PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.

Key Points: 
  • PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.
  • The Composition of Matter patent on the Novel Chemical Entity (NCE) PharmAla-1 will further strengthen the company’s position as a leading developer of Central Nervous System (CNS) pharmaceutical treatments.
  • PharmAla-1 is the first molecule of PharmAla’s extensive computational drug development pipeline, which PharmAla is announcing to the market in detail; PharmAla’s ALA and ABA patent families were developed via traditional drug discovery.
  • PharmAla is also excited to announce the acceptance of its review article titled "Balancing therapeutic efficacy and safety of MDMA and novel MDXX analogues as novel treatments for autism spectrum disorder" for publication in Psychedelic Medicine.

Enovix Establishes Research and Design Center in India

Retrieved on: 
Wednesday, July 26, 2023
University, Nanometre, Central Electro Chemical Research Institute, Computational chemistry, Electrochemistry, Renault India Private Limited, Reliance Industries, Data analysis, University of Massachusetts Amherst Department of Food Science, Machine learning, Silicon, Management

FREMONT, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, announced today it has established Enovix Research and Development Services India Private Limited (“Enovix India”) in Hyderabad.

Key Points: 
  • FREMONT, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, announced today it has established Enovix Research and Development Services India Private Limited (“Enovix India”) in Hyderabad.
  • The Enovix India team will develop advanced models to predict battery performance and support next-gen battery manufacturing and design.
  • “I’m pleased to announce we officially established our expansion into India with a dedicated R&D center in Hyderabad,” said Dr. Raj Talluri, President and CEO of Enovix.
  • “I am excited to lead the talented Enovix team and establish a strong presence in India,” said Dr. Saravanan.

Prestigious Institutions Use Panasas to Drive Academic Research Initiatives with HPC and AI workloads

Retrieved on: 
Tuesday, July 18, 2023
Data Management, Technology, Software, Research, Internet, Science, PB, Molecular biology, Informatics, Materials science, University, Freiberg University of Mining and Technology, LES, Agriculture, Teaching, 3D, Tomography, Computational chemistry, Automation, ParisTech, Marketing, Organization, Publication, UC, Machine learning, Rutherford Appleton Laboratory, HPC, MSI, CMI, Ultra, UMN, Growth, AI, United, Health, Environment, University of Minnesota Supercomputing Institute, RAL, Product strategy, Medical device, Renewable energy, Cryptocurrency, Panasas

“Research institutions are focused on uncovering breakthrough discoveries that in many cases will have an impact on all our lives.

Key Points: 
  • “Research institutions are focused on uncovering breakthrough discoveries that in many cases will have an impact on all our lives.
  • These research institutions cannot afford lost data, as it could set back the research program by months or even years.
  • With over 900 lead researchers and 4,500 users, MSI has relied on Panasas storage for many years to support their growing HPC and AI research initiatives.
  • To see a list of academic research projects, papers and publications that have used and cited Panasas, go here .

Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets

Retrieved on: 
Monday, July 17, 2023
Lead, Therapy, Cancer, Computational chemistry, Neoplasm, GPCR, Machine learning, VCS, Drug discovery, Membrane, Nursing, Medical imaging, Pharmaceutical industry, G protein-coupled receptor, Cumulus cloud

leadXpro will use its structural biology expertise, combining proprietary technology in protein structure determination, coupled with biophysical characterisation and computational modelling, to generate novel compounds.

Key Points: 
  • leadXpro will use its structural biology expertise, combining proprietary technology in protein structure determination, coupled with biophysical characterisation and computational modelling, to generate novel compounds.
  • Cumulus Oncology brings a team of successful life science entrepreneurs with deep oncology sector knowledge and a recognised track record in translational oncology drug development.
  • A GPCR portfolio company, created by Cumulus Oncology, focused on novel GPCR targets on tumours and the tumour microenvironment, will have the option to license the Lead compound series as well as resulting intellectual property from the research collaboration.
  • The founding team at Cumulus consists of successful life science entrepreneurs, scientists and a range of oncology drug development and pharma sector business professionals.